Guide

What to consider when building a channel strategy for a rare disease product

A checklist for biopharma companies

Evaluating channel strategy options for a rare disease product is an essential element of commercialization. Biopharma companies should ask themselves these five questions to ensure their novel therapy reaches the right patients at the right time.

Enter your information below to download the checklist. 

Pardot Form

Related resources

Webinar

Thinking like a regulator: De-risking first-cycle submission review

Article

An EU perspective on traversing the new transatlantic pharmaceutical partnership

Article

When CGT supply chains break down: 5 operational gaps that put patient outcomes at risk